Tools / Inside Trading Tracker
Inside Trading Tracker
Track insider trading activity at publicly traded companies to understand how executives are trading their shares.
ALX Oncology Holdings Inc. (ALXO) Insider Trading Activity
Healthcare • Biotechnology • 81 employees
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma. It also has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under Phase 1 trial for the treatment of breast cancer and other solid tumors; Quantum Leap Healthcare collaborative with an ADC, fam-trastuzumab deruxtecan-nxki, under Phase 1 trial for the treatment of patients with breast cancer; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; Sanofi with isatuximab and dexamethasone, under Phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma; Academic Gastrointestinal Cancer Consortium with pembrolizumab and cetuximab, under Phase 2 trial to treat refractory microsatellite stable metastatic colorectal cancer; and University of Pittsburgh with liposomal doxorubicin and pembrolizumab, under Phase 2 trial recurrent platinum-resistant ovarian cancer. In addition, the company has collaboration agreement with Tallac Therapeutics, Inc. for the development of ALTA-002, a potent immune activator targeted to myeloid cells in the tumor to promote innate and adaptive anti-cancer immune responses. It also has license agreements with Board of Trustees of the Leland Stanford Junior University, Selexis SA, and Crystal Bioscience, Inc. The company was incorporated in 2015 and is headquartered in South San Francisco, California.
Total Value
$5,502.55
Total Shares
8,739
Average Trade Value
$611.39
Most Active Insider
Hemrajani Rekha
Total Activity: $46,404
Largest Single Transaction
$46,404
by Hemrajani Rekha on Dec 2, 2024
30-Day Activity
0 Transactions
Volume: 0 shares
Value: $0
Name
|
Position
|
Date
|
Shares
|
Value
|
Holdings
|
Type
|
---|---|---|---|---|---|---|
Interim CFO
|
Jan 6, 2025 | 2,221 | $3,998 | 87,902 (-2.5%) | Sale | |
President Cso
|
Dec 30, 2024 | 10,796 | $17,060 | 580,714 (-1.9%) | Sale | |
Interim CFO
|
Dec 30, 2024 | 1,426 | $2,253 | 90,123 (-1.6%) | Sale | |
Dec 2, 2024 | 30,000 | $46,404 | 33,000 (+90.9%) | Purchase | ||
President Cso
|
Aug 14, 2024 | 1,937 | $4,997 | 591,510 (-0.3%) | Sale | |
Chief Executive Officer
|
Aug 14, 2024 | 2,191 | $5,653 | 169,429 (-1.3%) | Payment of Exercise Price | |
Chief Medical Officer
|
Aug 14, 2024 | 1,365 | $3,522 | 325,711 (-0.4%) | Sale | |
Svp, Finance and Cao
|
Aug 14, 2024 | 564 | $1,455 | 91,549 (-0.6%) | Sale | |
Chief Financial Officer
|
Aug 14, 2024 | 761 | $1,963 | 121,516 (-0.6%) | Payment of Exercise Price |